BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/13/2024 7:07:39 AM | Browse: 205 | Download: 739
 |
Received |
|
2024-06-05 04:49 |
|
Peer-Review Started |
|
2024-06-05 04:49 |
|
First Decision by Editorial Office Director |
|
2024-06-26 06:06 |
|
Return for Revision |
|
2024-06-26 06:06 |
|
Revised |
|
2024-07-09 14:17 |
|
Publication Fee Transferred |
|
2024-07-18 12:52 |
|
Second Decision by Editor |
|
2024-07-17 02:41 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-07-17 09:44 |
|
Articles in Press |
|
2024-07-17 09:44 |
|
Edit the Manuscript by Language Editor |
|
2024-08-01 01:35 |
|
Typeset the Manuscript |
|
2024-08-05 00:27 |
|
Publish the Manuscript Online |
|
2024-08-13 07:07 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: Https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Urology & Nephrology |
| Manuscript Type |
Case Report |
| Article Title |
Toripalimab in combination with chemotherapy effectively suppresses local recurrence and metastatic sarcomatoid renal cell carcinoma: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Ming-Zhu Gao, Nian-Fei Wang, Jin-You Wang, Li Ma and Yu-Cai Yang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| The Health Research Program of Anhui Province, China |
No. AHWJ2022b048 |
| The Research Foundation of Anhui Medical University, China |
No. 2021xkj164 |
| The Clinical Scientific Research Cultivation Project of the Second Affiliated Hospital of Anhui Medical University, China |
No. 2021LCZD04 |
|
| Corresponding Author |
Jin-You Wang, MD, Surgeon, Surgical Oncologist, Teacher, Department of Urology, The Second Affiliated Hospital of Anhui Medical University, Furong Road, Hefei 230601, Anhui Province, China. jinyouwang@126.com |
| Key Words |
Renal cell carcinoma; Sarcomatoid dedifferentiation; Immune checkpoint inhibitor; Chemotherapy; Case report |
| Core Tip |
Sarcomatoid renal cell carcinoma (SRCC) is a highly aggressive and uncommon malignant tumor of the kidney, which is associated with a rapid clinical course and unfavorable prognosis compared to conventional renal cell carcinoma. Traditional chemotherapy and targeted therapies have limited efficacy against SRCC. We present a rare case of recurrent and metastatic SRCC that achieved excellent outcomes with the combination of immunotherapy and chemotherapy. This study sheds new light on diagnostic and therapeutic approaches of SRCC. |
| Publish Date |
2024-08-13 07:07 |
| Citation |
Gao MZ, Wang NF, Wang JY, Ma L, Yang YC. Toripalimab in combination with chemotherapy effectively suppresses local recurrence and metastatic sarcomatoid renal cell carcinoma: A case report. World J Clin Cases 2024; 12(28): 6230-6236 |
| URL |
https://www.wjgnet.com/2307-8960/full/v12/i28/6230.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v12.i28.6230 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
